Top 15 Global Pharmaceutical Company Awards $1.1 Million in Studies to eResearchTechnology for Cardiac Safety Monitoring and Inf
December 28 2004 - 8:01AM
PR Newswire (US)
Top 15 Global Pharmaceutical Company Awards $1.1 Million in Studies
to eResearchTechnology for Cardiac Safety Monitoring and
Information Distribution Services Agreements Illustrate Continued
Importance of Central Cardiac Safety Monitoring Across All Phases
of Clinical Development PHILADELPHIA, Dec. 28
/PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT),
(NASDAQ:ERES), a leading provider of centralized
electrocardiographic (ECG) collection and interpretation services,
announced today that it has been awarded more than $1.1 million in
cardiac safety monitoring and services from a top 15 global
pharmaceutical organization for one of its key drug candidates in
late phase clinical trials. The award covers two Phase III studies,
for which eRT will provide comprehensive support, including
provision of 160 units of digital 12-lead ECG equipment designed to
facilitate collection of cardiac safety data that is subsequently
provided to eRT for analysis. eRT will perform digital collection,
measurement, interpretation, review, and distribution of cardiac
safety data through its EXPeRT(R) workflow enabled data handling
technology, the first solution in production that was designed
explicitly to meet emerging international regulatory guidance and
technical standards. "We are delighted to have been awarded these
two important studies, which leverage investigator networks
distributed across six continents and require eRT's substantial
equipment marshalling and logistics capabilities," said Scott
Grisanti, senior vice president of business development and chief
marketing officer at eRT. "Effective cardiac safety data collection
and analysis continues to be an important element in later phase
clinical development efforts to characterize cardiac effect of new
drugs on significant target patient populations." Based in
Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/)
is a provider of technology and services to the pharmaceutical,
biotechnology and medical device industries on a global basis. The
company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. The sponsor
may cancel this agreement at its sole discretion. As a result,
actual results may differ materially from any financial outlooks
stated herein. Further information on potential factors that could
affect the company's financial results can be found in the
company's Reports on Forms 10-K and 10-Q filed with the Securities
and Exchange Commission. DATASOURCE: eResearchTechnology, Inc.
CONTACT: Matt Hayden of Hayden Communications, +1-858-456-4533; or
Joan Sterlacci of eResearchTechnology, Inc., +1-908-203-6473 Web
site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles